drugset / Trial / NCT01161277

Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning

NCT01161277

Phase 4 Completed 54 enrolled Oslo University Hospital
RandomizedParallel-groupSingle-blindBasic science

Summary

The main objective is to investigate if the brain activation signature of a typical antipsychotic agent is dissociable from a newer drug with a pharmacological profile that differs from both typical and atypical antipsychotics since it is a potent partial D2 agonist. The method used to study this will be functional magnetic resonance imaging (fMRI).

Timeline

Start
2010-08
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aripiprazole Other / unclassified 5 mg
Comparator Aripiprazole Other / unclassified 10 mg
Comparator Haloperidol Other / unclassified 1 mg
Comparator Haloperidol Other / unclassified 2 mg

Indications